Charles River Laboratories International Inc (NYSE: CRL), a provider of products, models, services and guidance for biomedical research and drug development, on Wednesday announced an agreement with pharmaceutical company H. Lundbeck A/S to leverage Logica, an AI-powered drug discovery platform, in developing new therapies for neurological diseases.

Logica, developed in collaboration with biotechnology company Valo Health, integrates Valo's Opal Computational Platform with Charles River's drug discovery expertise to accelerate the creation of optimised small molecules for brain disease research.

Launched in 2022, Logica offers an end-to-end solution for drug discovery, utilising predictive models, in silico screening, and advanced chemistry capabilities to transform biological insights into preclinical candidates. Lundbeck aims to harness Logica's power to drive novel treatments for disorders of the central nervous system.

Charles River and Valo Health combine AI-driven data analysis with expertise in early-stage drug development, streamlining the path from target identification to candidate nomination. This collaboration aims to speed up the development of life-changing therapies while reducing costs and failure rates.